iCure Submits IND Application for Donepezil Patch Phase 1 Trial to US FDA

[Asia Economy Reporter Park Jihwan] iCure announced on the 31st that it has submitted an Investigational New Drug (IND) application for the Phase 1 clinical trial of donepezil patch to the U.S. Food and Drug Administration (FDA). The target disease is Alzheimer's disease.

This clinical trial aims to evaluate the steady-state pharmacokinetics of the 'IPI-401' patch administered transdermally twice a week and 'Aricept' tablets administered orally once daily in healthy adults.